Immutep Limited (IMMP): Price and Financial Metrics
IMMP Price/Volume Stats
| Current price | $2.25 | 52-week high | $3.90 |
| Prev. close | $2.20 | 52-week low | $1.50 |
| Day low | $2.20 | Volume | 90,000 |
| Day high | $2.32 | Avg. volume | 140,963 |
| 50-day MA | $2.44 | Dividend yield | N/A |
| 200-day MA | $2.15 | Market Cap | 197.84M |
IMMP Stock Price Chart Interactive Chart >
Immutep Limited (IMMP) Company Bio
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Latest IMMP News From Around the Web
Below are the latest news stories about IMMUTEP LTD that investors may wish to consider to help them evaluate IMMP as an investment opportunity.
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerMedia Release SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback has been received from the Paul-Ehrlich-Institut (“PEI”), a German regulatory authority and part of the Committee for Medicinal Products for Human Use (CHMP), regarding the planned TACTI-004 Phase III trial of e |
Immutep Receives A$2.6 million R&D Tax Incentive from French GovernmentMedia Release SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The “Crédit d’Impôt Recherche” (CIR), me |
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years agoFor many, the main point of investing is to generate higher returns than the overall market. But even the best stock... |
Immutep Announces Site Expansion for INSIGHT-003 Phase I TrialSYDNEY, AUSTRALIA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003 trial has been expanded to four sites across Germany including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim. This site expansion will support faster enrolment in this cost-efficient, inv |
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaMedia Release A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb trial evaluating efti in combination with pembrolizumab Efti has FDA Fast Track designation for first-line treatment of HNSCC SYDNEY, AUSTRALIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today a |
IMMP Price Returns
| 1-mo | -7.79% |
| 3-mo | -0.44% |
| 6-mo | 10.29% |
| 1-year | 38.04% |
| 3-year | -29.25% |
| 5-year | 18.42% |
| YTD | -6.25% |
| 2023 | 37.14% |
| 2022 | -46.65% |
| 2021 | 4.46% |
| 2020 | 75.42% |
| 2019 | -2.72% |
Continue Researching IMMP
Want to do more research on IMMUTEP Ltd's stock and its price? Try the links below:IMMUTEP Ltd (IMMP) Stock Price | Nasdaq
IMMUTEP Ltd (IMMP) Stock Quote, History and News - Yahoo Finance
IMMUTEP Ltd (IMMP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...